

CLINICAL TRIAL NOW ENROLLING

A Phase 0 study of **Infigratinib** in recurrent high-grade glioma participants scheduled for resection to evaluate CNS Penetration with PK triggered expansion cohort

PHYSICIAN INFORMATION

Dosing regimen - Phase 0

Infigratinib = 125mg PO QD x7 days

Inclusion Criteria

- Progression following Stupp regimen
- Surgical recommendation
- Sufficient archival tissue for eligibility testing that demonstrates:
 - FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3 translocation from NGS sequencing or IHC and RT-PCR
- ECOG \leq 2


Dosing regimen - Phase 2 (28-day cycles)

Infigratinib = 125mg PO QD x21 days

Exclusion Criteria

- Corneal or retinal disorder/keratopathy
- History of liver transplant
- Endocrine alterations of calcium/phosphate homeostasis
- Have used amiodarone within 90 days prior to first dose
- Current use of coumarin-derived anticoagulation
- Current use of carbamazepine, phenytoin, phenobarbital, and primidone
- Prior therapy with any MEK or FGFR inhibitor
- Significant cardiac disease
- QTcF > 470 msec

STUDY TIMELINE



PARTNER WITH US

When you refer a patient to the Ivy Center, we will partner with you and your team on a path forward.

To determine your patient's trial eligibility, please call **602.406.8605** or visit **IvyBrainTumorCenter.org**.